The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials.

Abstract

Breast cancer is a leading cause of cancer mortality in developed countries. We performed a meta-analysis of randomized clinical trials to investigate the effect of metformin on biomarkers associated with breast cancer outcomes and to explore the dose-response relationship. A systematic search was performed from onset of the database to January 2019 in MEDLINE/PubMed, SCOPUS, and Cochrane library to identify randomized clinical trials investigating the impact of metformin on insulin, glucose, CRP, leptin, body mass indices (BMI), cholesterol, Ki-67, and Homeostatic Model Assessment for Insulin-Resistance (HOMA-IR). Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI) using a random-effects models. Nine studies providing 1,363 participants were included in the meta-analysis. Pooled results showed a significant reduction in insulin (WMD: -0.99 U/ml, 95% CI -1.66, -0.33), glucose (WMD: -1.78ml/dl, 95% CI -2.96, -0.60), CRP (WMD: -0.60mg/l, 95% CI -0.88, -0.33), HOMA-IR (WMD: -0.45, 95% CI -0.77, -0.11), leptin (WMD: -2.44ng/ml, 95% CI -3.28, -1.61), BMI (WMD: -0.55kg/m2, 95% CI -1.00, -0.11), and Ki-67 (WMD: -4.06, 95% CI -7.59, -0.54). Results of the subgroup analyses showed that insulin, glucose, and BMI decreased more significantly when the duration of administering metformin intervention was above 4weeks. We did not observe non-linear changes in the dose-response relationship between metformin and biomarkers as outcomes. Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67.